Tianyin Pharma to form strategic alliance with Buchang Pharma

Tianyin Pharmaceutical (NYSE MKT: TPI), says TPI and Buchang Pharmaceutical plan to establish Tianyin-Buchang Strategic Alliance synergize and accelerate the growth of the company, boosting TPI's mTCM franchise focusing on its cardiovascular revenue driver Gingko Mihuan (GMOL).

TPI is a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API)

The Alliance platform will be established based on TPI's newly-completed and GMP-certified Qionglai Tianyin Facility (QLF) with the latest technologies and expanded production capacities in mTCM pre-extraction, purification and formulation manufacturing. It will integrate TPI's portfolio drugs especially core product portfolio with the possibility of integrating additional products beyond the current indication categories of cardiovascular, viral infection and immunology.